Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and …

…, EG Barbacci, LR Pustilnik, TA Smolarek… - … of Pharmacology and …, 1999 - ASPET
Phosphorylation of tyrosine residues on the epidermal growth factor (EGF) receptor (EGFr)
is an important early event in signal transduction, leading to cell replication for major human …

[PDF][PDF] Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from …

TA Smolarek, LL Wessner, FX McCormack… - The American Journal of …, 1998 - cell.com
Lymphangiomyomatosis (LAM) is a rare disease, of unknown etiology, affecting women
almost exclusively. Lung transplantation is the only consistently effective therapy for LAM. …

Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1

…, J Lin, JB Mills, JJ Xu, TA Smolarek - Drug Metabolism and …, 2005 - ASPET
The present study examined the interaction of four 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors (atorvastatin, lovastatin, and simvastatin in acid and lactone forms, and …

[HTML][HTML] Regions of homozygosity identified by SNP microarray analysis aid in the diagnosis of autosomal recessive disease and incidentally detect parental blood …

…, L Grote, L Bao, LJ Martin, TA Smolarek - Genetics in …, 2013 - nature.com
Purpose: The purpose of this study was to document the ability of single-nucleotide polymorphism
microarray to identify copy-neutral regions of homozygosity, demonstrate clinical utility …

Numerical chromosomal changes and risk of development of myelodysplastic syndrome–acute myeloid leukemia in patients with Fanconi anemia

…, B Lampkin, J Mo, K Myers, TA Smolarek - Cancer genetics and …, 2010 - Elsevier
Fanconi Anemia (FA) is an inherited bone marrow failure syndrome characterized by
congenital abnormalities, progressive marrow failure and predisposition to myelodysplastic …

Neonatal lung disease associated with TBX4 mutations

…, D Leino, RC Lombardo, TA Smolarek… - The Journal of …, 2019 - Elsevier
Variable lung disease was documented in 2 infants with heterozygous TBX4 mutations; their
clinical presentations, pathology, and outcomes were distinct. These findings demonstrate …

Redefined genomic architecture in 15q24 directed by patient deletion/duplication breakpoint mapping

AW El-Hattab, TA Smolarek, ME Walker, EK Schorry… - Human genetics, 2009 - Springer
We report four new patients with a submicroscopic deletion in 15q24 manifesting developmental
delay, short stature, hypotonia, digital abnormalities, joint laxity, genital abnormalities, …

[HTML][HTML] Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin®)

…, MW Leach, SA Ploch, JA Fohey, TA Smolarek - BioDrugs, 2014 - Springer
Background and Objectives Trastuzumab (Herceptin ® ) is a humanized monoclonal antibody
(mAb) that binds to the HER2 protein. PF-05280014 is being developed as a potential …

Copy number variation as a genetic basis for heterotaxy and heterotaxy-spectrum congenital heart defects

…, SR Lalani, TA Smolarek… - … of the Royal …, 2016 - royalsocietypublishing.org
Genomic disorders and rare copy number abnormalities are identified in 15–25% of patients
with syndromic conditions, but their prevalence in individuals with isolated birth defects is …

Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study

LB Baughn, JA Biegel, ST South, TA Smolarek… - Cancer genetics, 2015 - Elsevier
It is well documented that among subgroups of B-cell acute lymphoblastic leukemia (B-ALL),
the genetic profile of the leukemic blasts has significant impact on prognosis and …